Child and adolescent psychopharmacology in the new millennium: A workshop for academia, industry, and government

Joseph Deveaugh-Geiss, John March, Mark Shapiro, Paul J. Andreason, Graham Emslie, Lisa M. Ford, Laurence Greenhill, Dianne Murphy, Ernest Prentice, Rosemary Roberts, Susan Silva, James M. Swanson, Barbara Van Zwieten-Boot, Benedetto Vitiello, Karen Dineen Wagner, Barry Mangum

Research output: Contribution to journalArticle

38 Scopus citations

Abstract

Objective: To give academic researchers, government officials, and industry scientists an opportunity to assess the state of pediatric psychopharmacology and identify challenges facing professionals in the field. Method: Increased federal spending and the introduction of pediatric exclusivity led to large increases in pediatric psychopharmacology research in the 1990s. Despite the increase in research, concerns exist about methods and incentives for making new medications available for use in pediatric psychiatric disorders. In recognition of these concerns, the Duke Clinical Research Institute held a roundtable in September 2004. Participants from the National Institutes of Health, regulatory agencies, academia, and the pharmaceutical industry spoke about the effects of government regulations such as the U.S. Food and Drug Administration Modernization Act and the Pediatric Research Equity Act on pediatric research from academic, clinical, and industry perspectives, and bioethical considerations of such research. Conclusions: To ensure development of new drugs for treating psychiatric disorders in children and adolescents, we must address the challenges posed by the regulatory environment governing pediatric psychopharmacology research. Strategies were identified for improving the evidence base for psychopharmacologic interventions in youth before widespread use and for more effectively defining a research agenda for the future.

Original languageEnglish (US)
Pages (from-to)261-270
Number of pages10
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume45
Issue number3
DOIs
StatePublished - Mar 1 2006

Keywords

  • Best Pharmaceuticals for Children Act
  • Pediatric Research Equity Act
  • Pediatric depression
  • Pediatric psychopharmacology
  • Psychopharmacology trials

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Child and adolescent psychopharmacology in the new millennium: A workshop for academia, industry, and government'. Together they form a unique fingerprint.

  • Cite this

    Deveaugh-Geiss, J., March, J., Shapiro, M., Andreason, P. J., Emslie, G., Ford, L. M., Greenhill, L., Murphy, D., Prentice, E., Roberts, R., Silva, S., Swanson, J. M., Van Zwieten-Boot, B., Vitiello, B., Wagner, K. D., & Mangum, B. (2006). Child and adolescent psychopharmacology in the new millennium: A workshop for academia, industry, and government. Journal of the American Academy of Child and Adolescent Psychiatry, 45(3), 261-270. https://doi.org/10.1097/01.chi.0000194568.70912.ee